title: Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis.
abstract: The treatment for patients with lung cancer undergoing hemodialysis, who are frequently elderly and have poor performance status, becomes a more important subject. However, the feasibility of afatinib in patients with chronic renal failure undergoing hemodialysis has not, so far, been reported. Here, afatinib was administered to three patients with NSCLC harboring EGFR mutation and chronic renal failure undergoing hemodialysis. Pharmacokinetic (PK) data of afatinib supported the safety of afatinib treatment. After receiving their written informed consent from all patients, they were administered 30 mg afatinib daily with HD three times a week. We performed PK analyses of afatinib on days 1, 2, 10, and 11 after initial administration of afatinib. All three patients exhibited a partial response without any serious adverse events during the administration of afatinib. These PK data were similar to those of patients with normal organ function, which were previously reported. Our findings may be particularly useful given the current opportunity to use afatinib as a first-line treatment for EGFR-mutated NSCLC patients, providing an additional option for patients with impaired renal function.
authors.affiliation: Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Gunma, Japan.|Departments of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma, Japan.
authors.forename: Hisao
authors.initials: H
authors.lastname: Imai
authors.affiliation: Department of Oncology Clinical Development, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan. kkaira1970@yahoo.co.jp.
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Kaira
authors.affiliation: Department of Respiratory Medicine, Hidaka Hospital, Gunma, Japan.
authors.forename: Ichiro
authors.initials: I
authors.lastname: Naruse
authors.affiliation: Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Japan.|Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
authors.forename: Hideki
authors.initials: H
authors.lastname: Hayashi
authors.affiliation: Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Japan.|Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Iihara
authors.affiliation: Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Japan.
authors.forename: Yutaro
authors.initials: Y
authors.lastname: Kita
authors.affiliation: Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Mizusaki
authors.affiliation: Big Data Center for Integrative Analysis, Gunma University Initiative for Advance Research, Gunma, Japan.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Asao
authors.affiliation: Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Itoh
authors.affiliation: Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Japan.
authors.forename: Tadashi
authors.initials: T
authors.lastname: Sugiyama
authors.affiliation: Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Gunma, Japan.|Departments of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma, Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Minato
authors.affiliation: Departments of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma, Japan.
authors.forename: Masanobu
authors.initials: M
authors.lastname: Yamada
mesh_terms: D000077716:Afatinib; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000627:therapeutic use*; D006435:Renal Dialysis
chemical_list: D011799:Quinazolines; D000077716:Afatinib; D066246:ErbB Receptors
keywords: Afatinib; Chronic renal failure; EGFR mutation; Hemodialysis; Non-small-cell lung cancer